Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

CytRx arimoclomol clinical hold

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

CytRx hopes to begin a Phase II trial of its amyotrophic lateral sclerosis treatment arimoclomol by the end of 2005 based on communications from FDA regarding the agency's clinical hold on the trial, the Los Angeles firm says Aug. 10. FDA cited two actions required to lift the hold: submission of existing clinical information on CytRx' related small molecule agent bimoclomol, "which has been more extensively tested for safety in humans than arimoclomol"; and a protocol amendment to the study "to add specific clinical tests to be administered to patients enrolled in the study." CytRx announced the hold July 21...

You may also be interested in...



CytRx arimoclomol begins Phase II

CytRx is initiating a Phase II trial of its amyotrophic lateral sclerosis treatment arimoclomol, the firm says Sept. 22. CytRx received notification from FDA Sept. 21 regarding a clinical hold on the development program for the molecular chaperone activator announced last July (1Pharmaceutical Approvals Monthly August 2005, In Brief). The double-blind, placebo-controlled trial will enroll 80 patients from eight to ten U.S. centers. Primary endpoints are safety and tolerability; secondary endpoints include the revised ALS Functional Rating Scale. A second Phase II trial in 300 patients is slated to begin "soon after completion" of the present trial. CytRx announced FDA's decision to grant arimoclomol fast-track status Sept. 26...

IIL-Griffith Univ Readying Reasonably Priced COVID-19 Vaccine

The entry of India’s state-owned Indian Immunologicals and partner Griffith University in the COVID-19 vaccine race could potentially disrupt pricing dynamics. The alliance is developing a live-attenuated, single dose vaccine, which it hopes will be ready for launch in 18-24 months.

Cipla Granted Approval For First US Proventil Rival

Shortly after wrapping up a Phase III trial for its proposed generic Advair Diskus product in the US, Cipla has won FDA approval for the first generic Proventil HFA product, as it continues to build up steam in the US respiratory market.

Topics

UsernamePublicRestriction

Register

PS002991

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel